NASDAQ:GCTK GlucoTrack (GCTK) Stock Price, News & Analysis $1.36 -0.06 (-4.23%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.33▼$1.4850-Day Range$1.36▼$2.8852-Week Range$0.66▼$4.95Volume8,360 shsAverage Volume9,280 shsMarket Capitalization$7.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get GlucoTrack alerts: Email Address Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About GlucoTrack Stock (NASDAQ:GCTK)GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.Read More GCTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GCTK Stock News HeadlinesJuly 17, 2024 | americanbankingnews.comGlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Up 17.3% in JuneJune 20, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES THE APPOINTMENT OF ANDY BALO TO BOARD OF DIRECTORSJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.June 13, 2024 | globenewswire.comGLUCOTRACK REPORTS SUCCESSFUL COMPLETION OF FIRST REPORTED LONG-TERM PRECLINICAL STUDY OF ITS EPIDURAL GLUCOSE MONITORING SENSORJune 10, 2024 | globenewswire.comGLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCEJune 5, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES 90-DAY PRECLINICAL STUDY RESULTS THAT DEMONSTRATE SUSTAINED ACCURACY OF ITS IMPLANTABLE CONTINUOUS BLOOD GLUCOSE MONITORMay 17, 2024 | msn.comGCTK Stock Earnings: GlucoTrack Reported Results for Q1 2024May 16, 2024 | finance.yahoo.comGLUCOTRACK’S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDYJuly 27, 2024 | Darwin (Ad)Top Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.May 16, 2024 | globenewswire.comGLUCOTRACK'S EPIDURAL GLUCOSE MONITORING SENSOR DEMONSTRATES SUCCESSFUL 30-DAY SAFETY & PERFORMANCE IN LONG-TERM PRECLINICAL STUDYMay 16, 2024 | finanznachrichten.deGlucoTrack, Inc.: Glucotrack Announces Reverse Stock SplitMay 15, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES REVERSE STOCK SPLITMay 2, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATIONApril 26, 2024 | investing.comGlucoTrack director Drew Sycoff buys $230k in company sharesApril 26, 2024 | msn.comNasdaq Rises 0.5%; Tesla Shares Jump After Q1 ResultsApril 25, 2024 | msn.comGlucoTrack And 2 Other Stocks Under $1 Insiders Are BuyingApril 25, 2024 | finance.yahoo.comDirector and 10% Owner Drew Sycoff Acquires 182,540 Shares of GlucoTrack Inc (GCTK)April 22, 2024 | globenewswire.comGLUCOTRACK ANNOUNCES CLOSING OF PRIVATE PLACEMENTSee More Headlines Receive GCTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GlucoTrack and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/27/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:GCTK CUSIPN/A CIK1506983 Webwww.glucotrack.com Phone(201) 842-7715Fax972-8675-7850Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,100,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-207.55% Return on Assets-151.03% Debt Debt-to-Equity Ratio0.52 Current Ratio1.31 Quick Ratio1.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book1.77Miscellaneous Outstanding Shares5,479,000Free Float4,509,000Market Cap$7.45 million OptionableNot Optionable Beta0.06 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Paul V. Goode Ph.D. (Age 55)Chief Executive Officer Comp: $225kMr. Mark Tapsak Ph.D. (Age 55)Vice President of Technology Comp: $165kMs. Drinda Benjamin (Age 48)Vice President of Marketing Mr. James P. Thrower Ph.D. (Age 54)Vice President of Engineering Comp: $230kMr. Avner Gal MBA (Age 70)MSc.EE, Co-Founder, Chairman Emeritus, Consultant and Member of Scientific & Clinical Advisory Board Comp: $187.39kMr. David Malka BA (Age 59)Co-Founder Comp: $191.86kMr. James S. Cardwell (Age 63)Chief Financial Officer More ExecutivesKey CompetitorsMicrobot MedicalNASDAQ:MBOTBeyond AirNASDAQ:XAIRHoldco Nuvo Group D.GNASDAQ:NUVOMeihua International Medical TechnologiesNASDAQ:MHUAPixie Dust TechnologiesNASDAQ:PXDTView All CompetitorsInsidersDrew SycoffBought 36,508 shares on 4/22/2024Total: $230,000.40 ($6.30/share)View All Insider Transactions GCTK Stock Analysis - Frequently Asked Questions How have GCTK shares performed this year? GlucoTrack's stock was trading at $1.3075 on January 1st, 2024. Since then, GCTK shares have increased by 4.0% and is now trading at $1.36. View the best growth stocks for 2024 here. How were GlucoTrack's earnings last quarter? GlucoTrack, Inc. (NASDAQ:GCTK) released its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.60) earnings per share for the quarter. When did GlucoTrack's stock split? GlucoTrack's stock reverse split on Monday, May 20th 2024. The 1-5 reverse split was announced on Monday, May 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of GlucoTrack? Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GCTK) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlucoTrack, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlucoTrack With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
